At the workshop of the Shenyang Sinqi Ophthalmic Medications Holdings Co., Ltd. (hereinafter referred to as “Sinqi Ophthalmic Medications”), a new medicine for dry eye treatment was being produced on the automatic production line on October 14, 2020. Zirun®0.05% cyclosporine eye drops (II), an independently developed and patented ophthalmic drug for dry eye treatment, was approved for marketing and launched in June 2020. When asked how the company managed to stay on track despite the epidemic, Liu Jidong, chairman of Sinqi Ophthalmic Medications, said that the company attaches great importance to technological innovation and has secured a strong foothold in the market.